HSBC Starts Teva Pharma (TEVA) at Buy, 'innovative medicine division to become a driver of growth'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
December 14, 2023 8:30 AM ESTBiolojics BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases. Agreement builds on Teva's Pivot to Growth strategy to step up innovation on Teva's innovative pipeline. Teva to obtain exclusive worldwide rights to develop and commercialize BD9 multibody for potential treatment for Atopic Dermatitis and Asthma
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that uses computational biology and artificial intelligence to transform... More
